Allarity Therapeutics Appoints Jesper Høiland to Board

Allarity Therapeutics ( (ALLR) ) has issued an update.

On June 5, 2025, Allarity Therapeutics announced the resignation of Joseph W. Vazzano from its Board of Directors, effective June 30, 2025, and the appointment of Jesper Høiland as his replacement, effective the same date. Mr. Høiland, with over 30 years of experience in pharmaceutical commercialization, will also join several board committees and is expected to contribute significantly to the company’s strategic transition and commercialization efforts for its cancer treatment, stenoparib. His appointment comes during a period of growing clinical momentum for Allarity, and his expertise is anticipated to enhance the company’s operational focus and governance.

Spark’s Take on ALLR Stock

According to Spark, TipRanks’ AI Analyst, ALLR is a Underperform.

Allarity Therapeutics’ overall stock score is low due to significant financial challenges, including no revenue and consistent operational losses. Technical analysis shows a bearish trend with neutral momentum indicators, while valuation metrics are unfavorable with a negative P/E ratio and no dividend yield. These factors collectively suggest a high-risk investment with limited current appeal.

To see Spark’s full report on ALLR stock, click here.

More about Allarity Therapeutics

Allarity Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing personalized cancer treatments. The company is primarily engaged in the development of stenoparib, a novel PARP/tankyrase inhibitor for advanced ovarian cancer patients, utilizing its DRP® technology to create a companion diagnostic for patient selection. Allarity is headquartered in the U.S. with a research facility in Denmark, aiming to address unmet medical needs in cancer treatment.

Average Trading Volume: 1,219,459

Technical Sentiment Signal: Sell

Current Market Cap: $13.71M

See more insights into ALLR stock on TipRanks’ Stock Analysis page.